With regard to neoplastic B cells, there is evidence for deviation from this random use of V, families by certain tumors; the most studied group of these is chronic lymphocytic leukemia (CLL), in which biased expression of genes from the V,5 and V,6 families, accompanied by an underrepresentation of V,1 and V,2, has been reported.s.6 The neoplastic cell typical of CLL is usually CD5+ and normal or neoplastic B cells expressing this marker apparently derive from a separate lineage that, in both human and mouse, appears to be associated with synthesis of autoantibodies.' Considerably less is known of V, use by other Bcell tumors, although V, restriction could give rise to crossreactive idiotypes that might have a diagnostic or monitoring potential.' However, in a recent survey of 36 cases of follicular lymphoma, it was found that the fre- The sequence from the CLL was identical to the germline sequence, and the marginal zone lymphoma showed only 3 nucleotide changes, 2 of which gave rise to amino acid substitutions. In contrast, the sequence from the follicular lymphoma showed 29 nucleotide changes giving rise to 1 4 amino acid substitutions, which were scattered among the CDR and FW regions.
quency of V, family use was similar to that reported for normal blood lymphocytes, indicating no selective bias at this level, although there was a suggestion of nonrandom use of individual members of the V,4 family. ' During our studies of the idiotypic determinants expressed by cells of B-cell lymphomas, we raised a monoclonal anti-idiotype (anti-Id), 9G4, that recognizes a conformation-dependent Id encoded by the heavy chain of a member of the V,4 family, the V,4-2 1 gene.'-'' This deduction was made after profiling the reactivity of a large panel of sequenced Igs with the anti-Id"'," and has been confirmed by others.I2 An assessment of the involvement of this gene in a panel of human monoclonal Igs showed a highly restricted usage, with 0 of 55 IgGs and 1 of 19 IgM paraproteins being Id-positive; interestingly, the positive IgM was an autoantibody directed against the Ii carbohydrate antigen on the surface of red blood cells (RBCs), a so-called cold agglutinin,'and we have found subsequently that 48 of48 autoantibodies of this specificity express the Id and, in 8 cases studied by sequence analysis, use the V, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] This degree of restriction of a V, gene for an antibody specificity is highly unusual, and implies some structural requirement for the framework sequence encoded by the gene for antigen recognition. However, although the V,4-2 I gene appears mandatory for cold agglutinins, it can also be used by other antibodies, and has been reported to encode an IgG autoanti-DNA antibody."
Further investigation of Id expression showed that a significant proportion (-6%) of B cells in the fetal spleen were positive,16 and that the Id was present on CD5' B cells in cord blood." In fact, 24% of Epstein-Barr virus (EBV)-transformed B-cell clones established from CD5+ cord blood lymphocytes expressed the Id.I7 However, this figure does not necessarily reflect the frequency of Id-positive cells in the untransformed population, because there could be differences in the responses of B cells to EBV. Sequence analysis of 2 of 2 of these Id-positive EBV clones has confirmed usage of the V,4-2 1 gene (Dean et al, submitted for publication). Taken together, the evidence suggested that the V,4-2 1 gene was active early in normal B-cell maturation, was associated with CD5 positivity, and was used by neoplastic B cells involved in secreting autoanti-RBC antibodies. It was therefore of interest to investigate the various 224 Blood, VOI 82, NO 1 (July 1). 1993: PP 224-230
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categories of B-cell tumors for Id expression, anticipating that it would be found to be preferentially expressed by those tumor cells that are thought to arise from the early CD5 + lineage, ie, CLL.
MATERIALS AND METHODS
Cell suspension analysis. Blood was obtained from patients with CLL and from two patients with lymphoma; lymphocytes were separated using Ficoll-Hypaque. Cells were then suspended in warm medium (RPMI 1640, HEPES buffered) containing fetal calf serum (FCS; lo%), streptomycin (0.1 mg/mL), and penicillin (60 pg/mL) and washed twice. Cell surface antigens were analyzed in the FACS-SCAN (Becton Dickinson Lab Systems, Mountain View, CA) by indirect immunofluorescence using monoclonal anti-Ig reagents as described" and anti-CD5 (OKTl; ATCC, Rockville, MD), with fluorescein isothiocyanate (FIX)-labeled sheep antimouse IgG (Sigma Chemical Co, Poole, Dorset, UK) for detection. In one case of lymphoma (JJ), frozen cells were cytocentrifuged and analyzed by the sensitive single-stage alkaline phosphatase-antialkaline phosphatase (APAAP) technique, with sheep antimouse Ig as second bridging antibody followed by complexes of AP with its mouse antibody.16 The rat anti-idiotypic antibody, 9G4, which detects the VH4-21-associated Id, has been It is of the IgG2a subclass, and was used with a control subclass-matched rat antibody; detecting antibody was FITC-sheep antimouse IgG selected for cross-reactivity with rat IgG.
Tissue section analysis. Frozen tissue sections obtained from reactive lymph node, or from lymph node, spleen, and lung from patients with lymphoma were used to assess expression of Id. Cases of B-cell lymphoma were obtained from the frozen tissue files ofthe Department of Pathology, University ofsouthampton, and the original histologic diagnosis, made according to the Keil classification," was confirmed by independent review. Cryostat sections ( 5 pm) were air-dried at room temperature and stored at -70°C until required. Immediately before staining, the sections were fixed in acetone for 10 minutes and then stained by an indirect immunoperoxidase technique using HRP-rabbit antimouse IgG or HRP-rabbit antirat IgG, followed by development of reaction product by diaminobenzidine tetrahydr~chloride.'~ A diagnostic monoclonal antibody (MoAb) panel, containing antibodies against CD37, CD19, CD22, CD5, and CDlO, in conjunction with antibodies against Ig heavy and light chains, was used to confirm the presence of a B-cell tumor and allowed identification of areas of tumor involvement. Morphologically identified tumor cells were considered positive if a clear membrane immunoperoxidase reaction product could be seen in the frozen section.
Patients. Patients with a clinical diagnosis of CLL were identified from the routine immunology laboratory; those with a white blood cell count (WBC) ofgreater than 10 X 109/L and with tumor cells expressing the CD5 antigen were included in the study.
Three patients with Id-positive tumor cells were selected for nucleotide sequence analysis; each of these represented a distinct category of B-cell neoplasia. The first patient, KR (a 69-year-old woman) was a typical long-standing case of CLL, having a lymphocytosis (8 X 109/L) comprising small K-positive monomorphic lymphocytes. The second patient was a 63-year-old man, JJ, who presented in 1986 with a lymphocytosis and an enlarged spleen that was removed surgically. The histologic diagnosis was of a lymphocytic lymphoma with greater than 90% tumor cells in the involved spleen and bone marrow. However, a more recent assessment ofthe histologic appearance of the spleen has led to an assignment to the category of marginal zone lymphoma. The blood lymphocyte count was 7.5 X 109/L, of which the majorityi>95%) were X-positive tumor cells. These cells were stored frozen in liquid nitrogen for further analysis. The third patient, PS (a 43-year-old woman), presented in 1987 and had a lymph node removed surgically; the histologic diagnosis was of follicular lymphoma involving cells of centroblastic and centrocytic morphology. The patient also had a lymphocytosis (3.7 X 109/L) consisting of greater than 90% K-positive tumor cells; treatment with several courses of chemotherapy failed to control disease and tumor cells in the blood were at 4.5 X 109/L when collected for the study.
Active EBV was harvested from the marmoset cell line B95/8 and filtered (0.45 pm) before use. Blood lymphocytes from patient JJ were suspended in B95/8 culture fluid at 2 X IO6 cells/mL. After incubation for 1 hour, cells were centrifuged, resuspended in medium, and plated at 5 X IO5 cells/well in 200 pL medium in a 96-well plate. After a minimum of 4 days, cells received fresh medium and were monitored for growth before transfer. When in flasks, supernatant was taken for assay of IgM and Id by enzyme-linked immunosorbent assay (ELISA) as described,16 and cells were examined for clonality by staining for Id using the single-stage APAAP technique.
Cloning and sequencing of the productively rearranged VH
gene. For the V, of the EBV line established from JJ, the method of cloning and sequencing has been described in detail." For patients KR and PS, a more rapid method of direct sequencing from cDNA was used. Total RNA was isolated from -5 X IO6 tumor cells (>95% of the blood lymphocyte population) using RNAzol B (Cinna Biotecxlaboratories Inc, Houston, TX) and was reverse transcribed with Moloney murine leukemia virus reverse transcriptase and a Not-l-d(T),, primer (Pharmacia LKB, Uppsala, Sweden).
One-twentieth of the cDNA was amplified by polymerase chain reaction (PCR) using an oligonucleotide primer specific for the VH4 heavy chain leader (5'-ATGAAACACCTGTGGTTCTT) and a C p primer (5'-CGAGGGGGAAAAGGGTTGG).12 Amplified products were electrophoresed through a 1.5% agarose gel and purified using Geneclean I1 (Bio 10 1 Inc, La Jolla, CA). Purified DNA (100 ng) was sequenced directly by the dideoxy chain termination method with T7 DNA polymerase (Pharmacia) and 100 ng of the relevant PCR primer. PCR amplification and sequencing was performed three times.
Establishment of cell line from JJ.
RESULTS
Phenotypic analysis of blood cells from patients with
CLL. Samples of blood lymphocytes from patients with a diagnosis of CLL and WBC ofgreater than 10 X 109/L were analyzed in the FACS-SCAN. All expressed CD5, and those that were also clearly positive for surface Ig were selected for further study, giving a total of 8 1. The surface Ig was identified as IgMK (43) or IgMh (38), and ofthese, 2 IgMK and 1 IgMX also expressed the V,4-2 1-associated Id. The overall percentage of positivity ofthe Ig-expressing tumor cell populations in CLL was therefore 3.7% ( Table 1) .
The fact that the Id is expressed by -3% of B cells in normal lymph nodes has been described,16 and the detailed distribution of those cells in a typical follicle of a normal lymph node is shown in Fig I . Staining with anti-CD22, a pan-B-cell antigen (Fig lA) , shows a high density of B cells in the mantle zone, with a mixed population containing some B cells in the follicle center. Table I . In each case, the Id was expressed by the morphologically identifiable tumor cell population. and there were 9 of 62 clear positives (14.5%). which is significantly higher than that for CLL (. 1 > P > .05 by xz analysis).
Although numbers in each histologic category are too small to detect any significant differences, there is an indication of a low incidence in lymphocytic lymphoma (0 of 9 positive). consistent with the similarity of this neoplasm in morphology and behavior to CLL." Expression of CD5 was heterogeneous among the lymphocytic lymphomas, with 6 of 8 being positive ( 1 case was not evaluable).
An example of the pattern of staining in the follicle center of a lymph node infiltrated with Id-positive tumor is shown in Fig 2. Again, the pan-B-cell marker CD22 has been used to stain the total B-cell population (Fig 2A) . and the positive cells (marked with arrows). identifiable by darkly stained surface membranes. are clearly visible among a background of T cells, with the morphology of the stained population being strongly suggestive of tumor cells. This feature is also seen in Fig 2B using Table 2 and are indicated by an asterisk. For patient KR (CLL), the blood lymphocytes included 73% of IgMr-positive cells, all of which were positive for both Id and CD5: the majority of the remaining lymphocytes (22%) were T cells. For JJ (marginal zone lymphoma), the blood lymphocytes that were used for genetic analysis had a profile similar to that of the splenic tumor cells, with the majority (>95%) of cells expressing Id-positive IgMX. but no CD5, and few detectable T cells. After transformation with EBV. the same IgMld profile was maintained in greater than 95% of the cells in the line, and transformed cells secreted IgMX that was all idiotypic by ELISA.I6 consistent with a clonal population. For patient PS (follicular lymphoma), the Ig phenotype of tumor cells in the lymph node sections was IgMK and C D Y (Table 2) ; again, the neoplastic blood lymphocytes used for genetic analysis were of the same phenotype being greater than 90% positive for Id-positive IgMK.
Moleciilar analwis qf e.ypre.s.sed l/, genes qf KR, PS, and JJ. The nucleotide sequence of the V, region of the IgM from patient KR indicates that it is identical to the germline V,4-2 1 gene sequence (Fig 3) . The V, sequence of JJ is also derived from the V,4-2 1 germline gene, and there are only three mutations. However, as shown in Fig 4, two of the the PS V, (Fig 4) . and the gly to asp substitution via the which also includcs V,4-2 I . However, homology with the other members of the group is less than 90% and the VH4-2 I gene is the closest match. The D segments of KR and JJ are both long (Fig 4) and JH6 is used in each case. In fact. K R has a strctch of 26 nucleotides homologous to the D X P 4 germline gene and JJ hasa stretch of 23 nucleotides homologous to the DLR3 germline gene.'' with flanking sequences showing shorter sequence homologies to two other D segments. In contrast. the D segment of PS is a short sequence with a stretch of 7 nucleotides homologous to the DM? germline gene." In all thrcc cases. thcre are probable N-termind additions.
DISCUSSION
Anti-idiotypic antibodies have been used for more than 20 years to idcntify common structures in the variable regions of Ig moleculcs.'' Thc advcnt of monoclonal anti-Ids 
PS (1gH) --------A-----A-----------------A-----------------T--A-----------------------------------C-A-----------A-------------T-------A---------CDR2
I I Another interesting point is that the Id is expressed by autoantibodies that are specific for the I/i carbohydrate antigen on the RBC surface, the so-called cold agglutinins, and it appears that these autoantibodies are all encoded by the VH4-21 gene.Lo.'2,'4 This degree of restriction of a V, gene for a particular antibody is highly unusual; however, the V,4-2 I gene is not confined to anti-RBC antibodies, because it has been found also to encode autoanti-DNA antibodies."
VH4.21 (GL) GAGTGGATTGGG GAAATCAATCATAGTGGPAGCACCPACTACAACCCGTCCCTCPAGAGT CGAGTCACCATATCAGTAWCACGTCCAAGAACCAGTTCTCCCT~GCTGAGCTCTGTGACCGCCGCGGACACG KR
(IgH) _----------_ ---------------____-____________________-------
JJ (Ign) -_-----_--__ ----------_-____________________________------------------------------------------------------G------------------A---------
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Studies on fetal spleen showed that the Id was expressed early in development, being identifiable on -6% of B cells at 20 weeks of gestation.I6 The id was also detected on cord blood lymphocytes, in which it appeared to be preferentially expressed by CD5+ B cells.'7 This finding ofexpression ofan Id, known to be associated with both cold agglutinins and anti-DNA autoantibodies, by immature CD5+ B cells led us to anticipate that the Id would be present on CD5' neoplastic cells found in CLL, thereby supporting the proposed link between this normal cell population and the cells found in CLL.24 In fact, it is known that a significant proportion of such tumors synthesize autoantibodies, particularly rheumatoid factor. 25 The proposal that CLL could represent the neoplastic counterpart of immature B cells found in fetal spleen has been supported by the finding of common highfrequency cross-reactive Ids,26 some of which have been located to usage of certain V-genes, particularly V,IIIb.27 Assymetric usage of V, genes has been also reported for CLL, with increased involvement of v H 4 , vH5, and VH6.' However, the finding in this report is that expression of the Id associated with a member of the vH4 family, V,4-2 1, which --D----______________ ________________ ---------------R---------------- 
PS
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personal use only. on October 23, 2017. by guest www.bloodjournal.org From
V H GENE USAGE BY HUMAN B-CELL TUMORS
229
is expressed by -6% of fetal B cells, is found on only 3 of 8 1 (3.7%) cases of CD5' CLL. This indicates a consistency between the use of the V,4-21 gene by early B cells and its incidence in CLL. However, usage in CLL is low in comparison with other V, genes such as the 5 l p l V, 1 gene, which is associated with the G6 idiotope.26 For G6, although expression in the fetal spleen (6.9%) is comparable with our results for the VH4-2 1 -associated Id, expression by cases of CLL is high (20%).26 Loss of Id by mutation is an unlikely explanation for this relatively low level of expression because Vgenes in CLL tend to be unmutated"; also, the Id appears to tolerate quite extensive mutations without loss (Pascual et all0 and unpublished observations).
In contrast to CLL, the V,4-2 1 gene is used by neoplastic B cells that secrete IgM with cold agglutinin activity,I0,l2 and these tumors represent a significant proportion (1 3 of 105, ie, -12%) of the IgM-secreting neoplasms known as Waldenstrom's macr~globulinaemia.~~ Because the tumor cells tend not to be in the blood, there is less information on their CD5 status; however, in our preliminary studies using double staining for Id and CD5, we have found that the majority of cases (7 of This distribution is consistent with the specificity of the antibody for an Id that is effectively a V-region subgroup determi~~ant,~' and it appears to hold for the 9G4 Id that has a restricted specificity within the V,4 family.
The finding of 9 of 62 Id-positive cases among the lymphomas indicates that the V,4-2 1 gene is used at about the same frequency as in Waldenstrom's macroglobulinemia, and more commonly than in CLL (. 1 > P > .05 by x2 analysis). Previously, we found the Id-positive population of normal lymph node to represent 3.2% * 2.4% of the B cellsI6; this would suggest that the incidence of 14.5% in B-cell lymphomas reflects a preferential use of the V,4-2 1 gene. It will be ofinterest to expand the investigation ofthe various histologic types of lymphoma to see if there is any heterogeneity of expression among the groups. In a previous study of lowgrade follicular lymphoma, usage of V, families by tumor cells was comparable to that by normal B cells; however, use of individual members of the V,4 family appeared asymetric, with 3 of 8 of the tumors of the 1 1 to 14 member V,4 family being assigned to V,4-2 1 .'
To verify the association between Id expression and usage of the V,4-21 gene, we investigated the nucleotide sequences of randomly chosen B-cell tumors from the panel. Tumor-derived material was available from three patients, one a typical CLL and two having lymphomas of different histologic categories. For this particular V, gene, we have the advantage first, that it has a sequence that is quite distinct from other members of the V,4 family3' and second, that it has a very low degree of polymorphism, which allows recognition of mutations from the germline gene. 32 In fact, in a recent study of a random series of I 1 Id-positive clones established from six patients with infectious mononucleosis, we have found the V,4-2 1 to be in germline configuration and to be identical in nucleotide
The sequences obtained from the three tumors were closely related to the V,4-21 germline gene, which has a characteristic sequence particularly in FWl . In fact, that from patient KR was typical of the pattern found in C D Y CLL in being unmutated from germline." Little is known concerning V,-gene usage in marginal zone lymphoma, but it was interesting to note a very low level of mutations in this CD5-tumor. In contrast, the sequence of the V, gene from the follicular lymphoma PS showed 29 mutations, ofwhich 18 were replacements. This result is consistent with previous findings in follicular lymphoma, and may reflect the fact that normal B cells undergo hypermutation in the follicle center.33 In fact, in a recent report of a case of follicular lymphoma involving the V,4-2 1 gene, a similar number of mutations from germline (23) was found.34 However, if an analysis of the pattern of mutations in the two cases is made, there are differences, in that the changes in patient PS do not show a high rep1acement:silent ratio in the complementarity determining regions (CDRs) that may result from antigen selection. For patient PS, the analysis of mutations was performed in the same way. To assess the incidence of replacement and silent mutations, each change was assumed to have occurred independently and was designated as R or S and located in the CDRs or in framework regions ( F W R S ) .~~ The majority ofthe mutations (23) are located in FW regions, particularly FWR3, and the numbers of replacement and silent mutations in the FWRs ( 1 3R and 10s) and in the CDRs (5R and 1 S) are not sufficiently different from those expected from a random distribution and composition (FWRs: 14R and 8s; CDRs: 4R and 3s) to indicate a role for antigen selection. This finding contrasts with the published case in which there were 23 mutations, with a concentration of replacement mutations (1 1) in the CDRs compared with 4 expected.34 Clearly, more sequences of the V-genes of tumor cells are needed and the relatively nonpolymorphic V,4-2 1 gene is ideal for investigating this crucial point. At present, it is difficult to assess the role of chemotherapy in inducing mutations, because the patient in the previously reported and in the current study had both received chemotherapy. It will be of interest in the future to analyze V-gene sequences from patients at presentation. Even if chemotherapy is not a perturbing factor, it is possible that the situation in the lymph node is complicated in that the hypermutation mechanism may be activated in a B cell, but, after a neoplastic event, the tumor cell may or may not be influenced by antigen.
For
